CN Patent

CN117447407B — 一种JAK2抑制剂Pacritinib及其中间体的制备方法

Assigned to Daohe Weifang Pharmaceutical Technology Co ltd · Expires 2024-06-11 · 2y expired

What this patent protects

本发明涉及一种JAK2抑制剂Pacritinib及其中间体的制备方法，Pacritinib的制备方法包括如下步骤： （1）中间体G与中间体H于有机溶剂中，在碱、配体、钯催化剂的作用下，反应得到中间体I；（2）中间体I经烯烃复分解反应得到Pacritinib。

USPTO Abstract

本发明涉及一种JAK2抑制剂Pacritinib及其中间体的制备方法，Pacritinib的制备方法包括如下步骤： （1）中间体G与中间体H于有机溶剂中，在碱、配体、钯催化剂的作用下，反应得到中间体I；（2）中间体I经烯烃复分解反应得到Pacritinib。

Drugs covered by this patent

Patent Metadata

Patent number
CN117447407B
Jurisdiction
CN
Classification
—
Expires
2024-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Daohe Weifang Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.